Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sibling Study Could Lead to Better Treatments

By Drug Discovery Trends Editor | November 4, 2008

Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop.

In a study using siblings who have been diagnosed with colon cancer, scientists discovered similarities on a region of a particular chromosome, referred to as 7q31. Researchers believe that piece of genetic material may be causing a subset of colon cancers that run in families.

‘It’s those genetic similarities in colon cancer patients that would suggest that region holds a gene that’s causing colon cancer,’ says Deborah Neklason, PhD and lead investigator on the study.  Referred to as the Cancer Genetics Network ‘Sibling Pair Project,’ Neklason and other researchers analyzed the genetic material of 82 siblings. In addition to the discovery of a potential location of a cancer-causing gene, the research also shows siblings who share this genetic region tend to develop cancer 3.8 years earlier than siblings who do not. The study findings are published in the November 1, 2008 issue of Cancer Research.

Scientists already know roughly 30 percent of all colon cancers are a direct result of an inherited gene, but less than five percent of these genes have been identified.  ‘Those cases where the genes have been identified tend to be pretty dramatic,’ says Neklason. ‘Colon cancer develops at young ages and the cases are easier to figure out. It’s the other 25 percent that’s tough. These cases are more like sporadic colon cancer and are much more subtle,’ she says.

The findings could ultimately lead to a better understanding of the cellular process that results in cancer and its progression. It will likely pave the way for more targeted research that could someday result in a screening test to detect genetic forms of colon cancer.

Release Date: November 1, 2008
Source: University of Utah Health Services


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE